Annexon Biosciences is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients affected by classical complement-mediated diseases impacting the body, brain, and eye. The company's approach targets the classical complement cascade, specifically upstream C1q, to mitigate the inflammatory processes associated with various autoimmune, neurodegenerative, and ophthalmic conditions. With a robust pipeline of product candidates undergoing mid- to late-stage clinical trials, Annexon aims to deliver significant therapeutic benefits for diseases like Guillain-Barré Syndrome and Huntington's disease. Committed to diversity, equity, inclusion, and a patient-centered mission, Annexon fosters a collaborative environment where employees can impact patient lives while advancing their professional careers. With headquarters in Brisbane, CA, Annexon values diverse perspectives and encourages applicants from all backgrounds.